-
2024-518318-25-00
5
2020-06-24
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2023-504994-19-00
4
2020-06-12
Diffuse Large B-Cell Lymphoma
-
2022-501012-34-00
5
2020-02-27
Pulmonary Arterial Hypertension
-
2023-509908-15-00
10
2020-01-20
Mantle Cell Lymphoma
-
2024-515156-21-00
5
2020-01-09
Ulcerative Colitis
-
2024-511747-25-00
4
2019-12-23
B-cell non-Hodgkin lymphoma (NHL)
-
2024-518473-34-00
5
2019-11-20
Multiple Myeloma
-
2024-510626-89-00
5
2019-11-18
Non-Alcoholic Steatohepatitis (NASH)
-
2023-506832-33-00
5
2019-11-06
haemophilia A (HA) with inhibitors and haemophilia B (HB) with inhibit
-
2023-504718-31-00
10
2019-10-19
Moderately to Severely Active Ulcerative Colitis
-
2023-505980-36-00
5
2019-09-19
Primary progressive multiple sclerosis (PPMS)
-
2023-505810-12-00
5
2019-09-03
Lower limb spasticity
-
2023-506184-34-00
5
2019-08-09
Advanced Malignancies
-
2023-504930-23-00
5
2019-07-19
Episodic Migraine
-
2023-506153-38-00
5
2019-07-11
High-risk localized or locally advanced prostate cancer
-
2023-504932-16-00
5
2019-06-04
Muscle Invasive Bladder Cancer
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2023-509349-11-00
5
2019-03-22
Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or
-
2023-509602-29-00
5
2019-02-11
Patients with Limited Stage Small-Cell Lung Cancer (LS-SCLC)
-
2023-510015-19-00
5
2019-02-11
Patients with histologically or cytologically documented muscle-invasi
-
2023-507906-15-00
5
2019-01-30
Relapsing multiple sclerosis (RMS)
-
2022-501485-22-00
5
2018-12-18
Myelodysplastic syndrome (MDS)
-
2024-513912-89-00
10
2018-12-13
Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) Wit
-
2023-508463-71-00
5
2018-11-30
Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic L